0.37  0 (0%)		11-18 15:58
Open: High: 0.37 Volume: 0		Pre. Close: Low: 0.37 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.61	1-year :	0.87
Resists	First :	0.52	Second :	0.74
Pivot price	0.27
Supports	First :	0.17	Second :	0.14
MAs	MA(5) :	0.34	MA(20) :	0.28
	MA(100) :	1.88	MA(250) :	36.33
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	64.7	D(3) :	62.6
RSI	RSI(14): 50.7
52-week	High :	204.8	Low :	0.17

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SEEL ] has closed below upper band by 7.7%. Bollinger Bands are 86.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.41 - 0.41	0.41 - 0.41
Low:	0.38 - 0.38	0.38 - 0.39
Close:	0.38 - 0.39	0.39 - 0.39

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Fri, 18 Apr 2025
Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder - Seeking Alpha

Tue, 15 Oct 2024
Seelos Therapeutics Delisted From Nasdaq, Will Transition To OTC Market - Benzinga

Tue, 15 Oct 2024
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - Stock Titan

Tue, 15 Oct 2024
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - PR Newswire

Mon, 14 Oct 2024
SEEL stock touches 52-week low at $2.37 amid market challenges - Investing.com

Wed, 25 Sep 2024
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	0 (M)
Held by Insiders	0.4 (%)
Held by Institutions	41 (%)
Shares Short	171 (K)
Shares Short P.Month	25 (K)

EPS	351.04
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-135.5
Profit Margin	203.1 %
Operating Margin	-834.9 %
Return on Assets (ttm)	-261.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	11.8 %
Gross Profit (p.s.)	0
Sales Per Share	3.45
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-13 (M)
Levered Free Cash Flow	-34 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-0.01
Price to Sales	0.11
Price to Cash Flow	-0.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.